Literature DB >> 34031053

Bioavailability of Single-Dose SUBA-Itraconazole Compared to Conventional Itraconazole under Fasted and Fed Conditions.

Adriana M Rauseo1, Patrick Mazi1, Phoebe Lewis2, Bruce Burnett2, Stuart Mudge2, Andrej Spec1.   

Abstract

Conventional itraconazole (C-ITZ) suffers from absorption variability. SUBA-itraconazole (S-ITZ) is more bioavailable than C-ITZ at steady state in a fed condition, but there are no data comparing the two under a fasted state. An open-label, single-dose, randomized, bioequivalence study was performed comparing S-ITZ to C-ITZ capsules under fasted and fed conditions in healthy adults measuring itraconazole and hydroxyitraconazole plasma levels. This study demonstrated less variability of S-ITZ compared to C-ITZ capsules under fasted conditions.

Entities:  

Keywords:  bioavailability; endemic mycoses; itraconazole; pharmacokinetics

Mesh:

Substances:

Year:  2021        PMID: 34031053      PMCID: PMC8284459          DOI: 10.1128/AAC.00134-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Bioequivalence approaches for highly variable drugs and drug products.

Authors:  Sam H Haidar; Barbara Davit; Mei-Ling Chen; Dale Conner; LaiMing Lee; Qian H Li; Robert Lionberger; Fairouz Makhlouf; Devvrat Patel; Donald J Schuirmann; Lawrence X Yu
Journal:  Pharm Res       Date:  2007-09-22       Impact factor: 4.200

2.  The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.

Authors:  A Van Peer; R Woestenborghs; J Heykants; R Gasparini; G Gauwenbergh
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis.

Authors:  John N Galgiani; Neil M Ampel; Janis E Blair; Antonino Catanzaro; Francesca Geertsma; Susan E Hoover; Royce H Johnson; Shimon Kusne; Jeffrey Lisse; Joel D MacDonald; Shari L Meyerson; Patricia B Raksin; John Siever; David A Stevens; Rebecca Sunenshine; Nicholas Theodore
Journal:  Clin Infect Dis       Date:  2016-07-27       Impact factor: 9.079

4.  Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers.

Authors:  J A Barone; J G Koh; R H Bierman; J L Colaizzi; K A Swanson; M C Gaffar; B L Moskovitz; W Mechlinski; V Van de Velde
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

5.  Treatment of disseminated histoplasmosis in advanced HIV using itraconazole with increased bioavailability.

Authors:  Rekha P Mangalore; Michael A Moso; Katie Cronin; Katrina Young; James H McMahon
Journal:  Int J STD AIDS       Date:  2018-08-16       Impact factor: 1.359

6.  Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group.

Authors:  J Wheat; R Hafner; A H Korzun; M T Limjoco; P Spencer; R A Larsen; F M Hecht; W Powderly
Journal:  Am J Med       Date:  1995-04       Impact factor: 4.965

7.  A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation.

Authors:  A P Grigg; M Brown; A W Roberts; J Szer; M A Slavin
Journal:  Bone Marrow Transplant       Date:  2004-09       Impact factor: 5.483

8.  Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects.

Authors:  Julian Lindsay; Stuart Mudge; George R Thompson
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 9.  Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

Authors:  H Ruth Ashbee; Rosemary A Barnes; Elizabeth M Johnson; Malcolm D Richardson; Rebecca Gorton; William W Hope
Journal:  J Antimicrob Chemother       Date:  2013-12-29       Impact factor: 5.790

10.  Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison for a 3-Day Loading Dose Regimen and 15-Day Steady-State Administration of SUBA-Itraconazole and Conventional Itraconazole Capsules in Healthy Adults.

Authors:  George R Thompson; Phoebe Lewis; Stuart Mudge; Thomas F Patterson; Bruce P Burnett
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

View more
  1 in total

Review 1.  Blastomycosis-Some Progress but Still Much to Learn.

Authors:  Matthew F Pullen; Jonathan D Alpern; Nathan C Bahr
Journal:  J Fungi (Basel)       Date:  2022-08-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.